Loading...
Docoh

Unicycive Therapeutics (UNCY)

News

From Benzinga Pro
12 Health Care Stocks Moving In Wednesday's After-Market Session
4 May 22
Movers
Gainers 1Life Healthcare (NASDAQ:ONEM) shares moved upwards by 22.4% to $9.58 during Wednesday's after-market session. The market value of their outstanding shares is at $1.8 billion. The company's, Q1 earnings came out today.
12 Health Care Stocks Moving In Monday's After-Market Session
2 May 22
Movers
Gainers
12 Health Care Stocks Moving In Wednesday's After-Market Session
27 Apr 22
Movers
Gainers Unicycive Therapeutics (NASDAQ:UNCY) shares moved upwards by 9.9% to $1.0 during Wednesday's after-market session. The company's market cap stands at $15.0 million.
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
29 Mar 22
Movers
Gainers China SXT Pharmaceuticals (NASDAQ:SXTC) stock moved upwards by 45.0% to $0.29 during Tuesday's pre-market session. The company's market cap stands at $8.5 million.
12 Health Care Stocks Moving In Thursday's Pre-Market Session
17 Mar 22
Pre-Market Outlook, Markets, Movers
22 Stocks Moving in Thursday's Pre-Market Session
17 Mar 22
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers TD Holdings, Inc. (NASDAQ: GLG) rose 81.2% to $0.43 in pre-market trading after the company reported FY21 results.
Benzinga's Top Ratings Upgrades, Downgrades For March 16, 2022
16 Mar 22
Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings
Upgrades
Unicycive Announces Acceptance Of Two Preclinical Data Sets To Be Presented At The European Renal Association Congress
16 Mar 22
News, FDA, Events
Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announced that two in-vivo data sets highlighting the
Maxim Group Initiates Coverage On Unicycive Therapeutics with Buy Rating, Announces Price Target of $3
16 Mar 22
News, Price Target, Initiation, Analyst Ratings
Maxim Group analyst Jason McCarthy initiates coverage on Unicycive Therapeutics (NASDAQ:UNCY) with a Buy rating and announces Price Target of $3.
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
15 Mar 22
Pre-Market Outlook, Markets, Movers
Stocks That Hit 52-Week Lows On Tuesday
8 Mar 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
Tuesday's session saw 729 companies set new 52-week lows.
12 Health Care Stocks Moving In Thursday's After-Market Session
24 Feb 22
Movers
Gainers Unicycive Therapeutics (NASDAQ:UNCY) shares rose 27.9% to $1.65 during Thursday's after-market session. The company's market cap stands at $24.7 million.

Press releases

From Benzinga Pro
Glancy Prongay & Murray LLP Announces Investigation of Unicycive Therapeutics, Inc.
14 Apr 22
Press Releases
Glancy Prongay & Murray LLP ("GPM") announces its investigation of Unicycive Therapeutics, Inc. (NASDAQ:UNCY) concerning the Company and its directors' and officers' possible violations of state laws. If you own
Unicycive Announces Key Opinion Leader Event Highlighting Novel Treatments in Kidney Diseases
14 Apr 22
News, Health Care, Press Releases
LOS ALTOS, Calif., April 14, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announced that there
Unicycive To Ring the Nasdaq Closing Bell on March 29, 2022
23 Mar 22
News, Markets, Press Releases
LOS ALTOS, Calif., March 23, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announced that the
Unicycive Announces Acceptance of Two Preclinical Data Sets to be Presented at the European Renal Association Congress
16 Mar 22
News, Press Releases
LOS ALTOS, Calif., March 16, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announced that two
Unicycive to Present at Upcoming March Investor Conferences
3 Mar 22
Press Releases
LOS ALTOS, Calif., March 3, 2022 /PRNewswire/ -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announced that Shalabh